Suzhou Zelgen Biopharmaceuticals Co.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Suzhou Zelgen Biopharmaceuticals Co. sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

Suzhou Zelgen Biopharmaceuticals Co.: 2 sponsored US clinical trials, 2 recruiting.

Suzhou Zelgen Biopharmaceuticals Co. sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelofibrosis, with 1 trials.

Mid-pack sponsor footprint

Suzhou Zelgen Biopharmaceuticals Co. is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Suzhou Zelgen Biopharmaceuticals Co. pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Myelofibrosis (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Suzhou Zelgen Biopharmaceuticals Co.: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Suzhou Zelgen Biopharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Suzhou Zelgen Biopharmaceuticals Co.1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Suzhou Zelgen Biopharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Suzhou Zelgen Biopharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Suzhou Zelgen Biopharmaceuticals Co. page

2 registered trials is a research-attention snapshot, not an endorsement of Suzhou Zelgen Biopharmaceuticals Co. or any single study.

  • 2 of Suzhou Zelgen Biopharmaceuticals Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Myelofibrosis is the condition Suzhou Zelgen Biopharmaceuticals Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelofibrosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Suzhou Zelgen Biopharmaceuticals Co. pipeline card: 2 registered trials from official public datasets.Report a data error.